Koāte-DVI is indicated for the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor, Factor VIII. Koāte-DVI provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia. Koāte-DVI contains naturally occurring von Willebrand factor, which is co-purified as part of the manufacturing process*.

*Koāte-DVI has not been investigated for efficacy in the treatment of von Willebrand disease, and hence is not approved for such usage.

FOR PATIENTS

FOR HEALTHCARE PROVIDERS